NCHR Testimony at FDA Meeting on Developing Antibiotics for Bacteria That Rarely Cause Infection

April 13, 2017. Developing antibiotics for single bacterial species that infrequently cause infections is difficult. We as a society and as patients want these treatments. However, having ineffective drugs marketed for these specific bacterial species does not help patients and may harm them, in addition to contributing to healthcare costs, which are already higher in the US than other countries where people live years longer. If the FDA wants to be more patient-centered, it needs to ensure that new antibiotics actually work for the intended patients before they are approved. New drugs should be scientifically tested on patients who know that they are participating in a well-designed clinical trial that contributes to knowledge, not by patients who think that they are receiving a proven treatment.

Read More »

NCHR Comment on the USPSTF’s Draft Recommendations for Vision Screening in Young Children

March 27, 2017. NCHR supports USPSTF’s draft recommendation for vision screening in young children as well as their broader efforts to improve the health of all Americans by making evidence-based recommendations about clinical preventive services. As more information becomes available, we encourage the provision of additional recommendations about procedures that improve the benefits of vision tests for children and their families.

Read More »

NCHR Comment to EPA on Procedures for Prioritization of Chemical for Risk Evaluation

March 20, 2017. The 2016 Frank H. Lautenberg Chemical Safety for the 21st Century Act is the first major reform of the 1976 Toxic Substance Control Act. This law requires the EPA to systematically prioritize and assess the tens of thousands of existing chemicals. We support many aspects of the proposed rule on EPA’s steps for prioritization, but want to caution the EPA against designating chemicals as low-priority primarily because there is little information about risks.

Read More »